J. Goldman & Co’s Clovis Oncology, Inc. CLVS Stock Holding History

J. Goldman & Co’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-13,000	Closed	-$828K	–	440
2017 Q1	$828K	Buy	+13,000	New	+$790K	0.04%	261

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

J. Goldman & Co's CLVS Position: Q2 2017 in Review

J. Goldman & Co sold out of Clovis Oncology, Inc. (CLVS) in Q2 2017, closing a stake of 25,700 shares — an estimated $1.64M sold.

J. Goldman & Co first reported a position in CLVS in Q2 2016 and held it in 3 quarters. The position peaked at $4.61M in Q2 2016. 271 funds tracked by Wall St. Rank hold CLVS as of Q2 2017.

J. Goldman & Co reported no remaining Clovis Oncology, Inc. position as of Q2 2017 after selling out during the quarter.
J. Goldman & Co sold 25,700 Clovis Oncology, Inc. shares in Q2 2017, an estimated $1.64M.
J. Goldman & Co first reported a position in Clovis Oncology, Inc. in Q2 2016 and held it in 3 quarters.
J. Goldman & Co's Clovis Oncology, Inc. position peaked at $4.61M in Q2 2016.
271 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2017.

Based on J. Goldman & Co's 13F filing for Q2 2017, filed 14 Aug 2017.